leadf
logo-loader
viewBraveheart Investment Group

Braveheart value rockets as coronavirus shines light on portfolio

Snapshot

  • Braveheart is an investment company with six core investments
  • Significant potential at investee companies Paraytec, Kirkstall and Gyrometric
  • Coronavirus has highlighted the potential within the portfolio
Braveheart

Quick facts: Braveheart Investment Group

Price: 38.5 GBX

AIM:BRH
Market: AIM
Market Cap: £13.9 m
Follow

What it does 

Braveheart Investment Group PLC (LON:BRH) is an AIM-listed investment company with six strategic investments in its portfolio alongside other historical investments.

Key investments include Kirkstall, UV light detection group Paraytec, propeller and rotating shaft monitoring group Gyrometric Systems, microscope imaging firm PhaseFocus and Sentinel Medical, a spin-out of Paraytec developing technology to detect cancer cells in urine.

The company also has a 51.72% stake in Pharm2Farm Limited (P2F), a plant nutrients specialist.

 

How it is doing

A new antiviral face mask that can kill COVID-19 will go on sale by the end of the year.

This follows a flurry of activity at Braveheart investee company Pharm2Farm (P2F), which has developed a textile coating incorporating nanoparticles with long-lasting virucidal properties.

It now has testing results from two independent labs that show the mask textile has a ‘kill rate’ of over 90% for up to seven hours, meeting the requirements for ISO 18184 certification.

Braveheart’s sale of its 51.72% stake in P2F to Remote Monitored Systems PLC (LON:RMS) is expected to complete on November 5. As a result Braveheart will own 37.12% of RMS.

Meanwhile, Paraytec Limited has completed proof of concept trials for a coronavirus test it is developing with the University of Sheffield.

Following the achievement of proof of concept for the optical detection system on October 5, the focus has been on the proof of concept trials for the capture and signal generation modules for the test.

 

What the boss says: Trevor Brown, chief executive

"This is a phenomenal achievement for all concerned. The inspirational leadership and innovative brilliance of Professor Carl Smythe and his talented team have resulted in proof of concept in a little over four months," he commented on Paraytec's update.


 

Video

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Braveheart Investment Group named herein, including the promotion by the Company of Braveheart Investment Group in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Braveheart Investment Group Pharm2Farm designs antiviral face mask to kill...

Braveheart Investment Group PLC (LON:BRH) investee company Pharm2Farm's (P2F) Gareth Cave talks to Proactive London about their new antiviral face mask that can kill coronavirus (COVID-19). Cave talks through the technology behind the mask, which is says is much stronger than the standard...

4 weeks, 2 days ago

2 min read